The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXeros Tech Regulatory News (XSG)

Share Price Information for Xeros Tech (XSG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.325
Bid: 1.30
Ask: 1.35
Change: 0.00 (0.00%)
Spread: 0.05 (3.846%)
Open: 1.325
High: 1.325
Low: 1.325
Prev. Close: 1.325
XSG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate changes

12 Feb 2019 07:00

RNS Number : 6939P
Xeros Technology Group plc
12 February 2019
 

12 February 2019

 

Xeros Technology Group plc

 

Directorate changes

 

Xeros Technology Group plc (AIM: XSG, 'Xeros', 'the Group'), the developer and provider of water saving technologies with multiple commercial applications, today announces that John Samuel has resigned as non-executive Chairman with immediate effect. David Armfield, who joined the Board in June 2018, has been appointed interim non-executive Chairman.

 

Separately David Baynes, a director of IP Group plc, joins the Board as a non-executive director today. He is a Chartered Accountant and will Chair the Audit Committee.

David Graham Baynes, aged 55, is currently Chief Operating Officer at IP Group plc and has been on its Board since March 2014. He was previously a co-founder and the CEO of AIM-listed Fusion IP plc and was also a co-founder, CEO and CFO of Toad plc (now 21st Century Technology plc). David also worked at Celsis International plc from its incorporation to its flotation on the full list of the London Stock Exchange and was previously CFO of Codemasters Limited, at the time, the UK's largest privately-owned games company.

 

David Armfield, interim non-executive Chairman, commented:

 

"On behalf of the Board, I would like to thank John for his considerable contribution as Chairman since the business listed in March 2014. It has progressed from early stage technology development to its current position of having multiple proprietary applications in the process of commercialisation. As he steps down in order to devote more time to his other executive and non-executive Board roles - we wish him well for the future. I would also like to welcome David to the Board who brings with him a huge amount of experience in growth companies, both private and public."

 

 

Enquiries:

Xeros Technology Group plc

David Armfield, interim non-executive Chairman

Tel: 0114 321 6328

 

 

 

Jefferies International Limited (Nominated Adviser and Joint Broker)

Simon Hardy / Will Soutar

Tel: 020 7029 8000

 

 

Berenberg (Joint Broker)

Chris Bowman / Ben Wright / Laure Fine

Tel: 020 3207 7800

 

 

Instinctif Partners

Adrian Duffield / Kay Larsen / Chantal Woolcock

 

Tel: 020 7457 2020

 

AIM Rules for Companies Schedule 2 (g) information

 

David Baynes, holds or has held the following directorships in the five years preceding his appointment to the Xeros Technology Group Plc Board.

 

Current directorships:

 

 

Director, IPG USA (LP) Limited

November 2018 - Present

Director, Imperial Innovations Limited

Director, Touchstone Innovations Investments Limited

February 2018 - Present

February 2018 - Present

Director, Imperial College Company Maker Limited

February 2018 - Present

Director, Innovations Limited Partner Ltd

February 2018 - Present

Director, Touchstone Innovations Plc

December 2017 - Present

Director, IP2IPO Asia-Pacific Limited

February 2017 - Present

Director, IP2IPO US Partners Limited

December 2016 - Present

Director, IP2IPO Americas Limited

November 2016 - Present

Director, IP2IPO Carry Partner Limited

September 2016 - Present

Director, IP2IPO Portfolio (GP) Limited

September 2016 - Present

Director, Top Technology Ventures Limited

August 2015 - Present

Finance Director, IP2IPO FI Limited

September 2014 - Present

Director, Intelligent Ultrasound Group Plc

August 2014 - Present

Finance Director, IP2IPO Limited

April 2014 - Present

Finance Director, North East Technology (GP) Limited

April 2014 - Present

Finance Director, IP Venture Fund (GP) Limited

April 2014 - Present

Director, IP Group Plc

March 2014 - Present

Director, MedaPhor Limited

June 2010 - Present

Director, Morvus

September 2010 - Present

Director, Demasq Limited

April 2008 - Present

Director, Phase Focus Limited

June 2006 - Present

Director, Fusion IP Nottingham Limited

March 2008 - Present

Director, Fusion IP Two Limited

March 2008 - Present

Director, Fusion IP Cardiff Limited

November 2006 - Present

Finance Director, Biofusion Licensing (Sheffield) Limited

September 2006 - Present

Director, Fusion IP Limited

November 2004 - Present

Director, Out Of The Blue Consulting Limited

March 2003 - Present

Director, Fusion IP Sheffield Limited

January 2003 - Present

 

Previous directorships, last 5 years:

 

 

Director, Arthurian Life Sciences Limited

July 2013 - July 2015

Director, Rhedyn Limited

March 2013 - March 2016

Director, Wound Genetics Limited

November 2012 - September 2016

Director, Proflu Limited

November 2012 - July 2016

Director, Wound Genetics Therapeutics Limited

November 2012 - September 2016

Director, Wound Genetics Prognostics Limited

November 2012 - September 2016

Director, Rheometrix Microsystems Limited

April 2012 - September 2016

Director, Perlemax Limited

January 2012 - September 2014

Director, Medipex Limited

April 2011 - September 2014

Director, Mesuro Limited

September 2008 - September 2014

Director, Magnomatics Ltd

June 2008 - November 2014

Director, Biohydrogen Limited

March 2007 - September 2016

Director, Alesi Surgical Limited

March 2007 - January 2017

Director, Medella Therapeutics Limited

February 2007 - June 2014

CEO, Mantelum Limited

June 2006 - September 2016

Director, Diurnal Limited

October 2005 - October 2014

 

David Baynes was a Director of CellTran Limited, which developed a skin treatment for burns and chronic wounds using a patient's living cells but went into administration in May 2008 after running out of funds for product development and distribution.

 

There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.

 

Notes to Editors

 

Xeros Technology Group plc (LN: XSG) is a platform technology company that is reinventing water intensive industrial and commercial processes.

 

Xeros' uses its patented XOrbTM technologies to significantly reduce the amount of water used in a number of major applications with the remaining water becoming far more efficient in either affixing or removing molecules from substrates such as fabrics and garments. The result being significant improvements in economic, operational and sustainability outcomes.

 

Xeros has three divisions working in the garment finishing (Textile Technologies), tanning (Tanning Technologies, branded Qualus) and cleaning/laundry (Cleaning Technologies) markets. In cleaning/laundry, the company has three applications covering domestic laundry, commercial laundry (branded "Hydrofinity") and the cleaning of high-performance workwear (branded "Marken").

 

For more information, please visit - http://www.xerostech.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAFMGMZRMLGLZM
Date   Source Headline
3rd May 20247:00 amRNSAppointment of Board Observer
1st May 20242:14 pmRNSTotal Voting Rights
30th Apr 20241:45 pmRNSTR-1
29th Apr 20245:20 pmRNSTR-1
29th Apr 20243:40 pmRNSTR-1
29th Apr 20243:14 pmRNSTR-1
29th Apr 20242:18 pmRNSTR-1
29th Apr 20242:14 pmRNSTR-1
26th Apr 20245:01 pmRNSTR-1
26th Apr 202412:09 pmRNSTR-1
25th Apr 20242:09 pmRNSResult of GM, Director Dealings and TVR
19th Apr 20241:13 pmRNSResult of Retail Offer
9th Apr 20242:58 pmRNSTR-1
8th Apr 20244:30 pmRNSPosting of Circular and Notice of General Meeting
8th Apr 20243:56 pmRNSTR-1
5th Apr 202410:22 amRNSTotal Voting Rights
4th Apr 20246:29 pmRNSResult of Fundraising
4th Apr 20244:49 pmRNSRetail Offer
4th Apr 20244:40 pmRNSFundraising to raise up to £5.5 million
11th Mar 20247:00 amRNSAlex Tristram joins the Board as Finance Director
8th Feb 20245:03 pmRNSHolding(s) in Company
8th Feb 20244:27 pmRNSHolding(s) in Company
8th Feb 20242:51 pmRNSHolding(s) in Company
8th Feb 20249:07 amRNSHolding(s) in Company
7th Feb 20242:05 pmRNSHolding(s) in Company
6th Feb 20243:24 pmRNSHolding(s) in Company
6th Feb 202410:22 amRNSHolding(s) in Company
5th Feb 20247:00 amRNSTR-1
2nd Feb 20247:00 amRNSExercise of Warrants, Issue of Equity and TVR
29th Jan 202412:00 pmRNSHolding(s) in Company
26th Jan 20241:35 pmRNSExercise of Warrants and Total Voting Rights
19th Jan 20243:31 pmRNSExercise of warrants and Total Voting Rights
18th Jan 20242:37 pmRNSHolding(s) in Company
18th Jan 20247:00 amRNSDirector/PDMR Shareholding
17th Jan 20242:22 pmRNSHolding(s) in Company
16th Jan 20244:38 pmRNSHolding(s) in Company
15th Jan 20245:32 pmRNSHolding(s) in Company
9th Jan 20242:33 pmRNSHolding(s) in Company
8th Jan 20246:00 pmRNSHolding(s) in Company
8th Jan 20247:00 amRNSHolding(s) in Company
2nd Jan 20241:56 pmRNSBlock listing Interim Review
21st Dec 20231:38 pmRNSResults of Warrant Holder Meeting
15th Dec 202311:55 amRNSHolding(s) in Company
4th Dec 20237:00 amRNSCircular Posting & Warrant Holder Meeting Notice
29th Nov 20237:00 amRNSTerms of Warrants Consultation and Trading Update
20th Nov 20233:45 pmRNSHolding(s) in Company
14th Nov 20235:01 pmRNSHolding(s) in Company
8th Nov 20233:29 pmRNSHolding(s) in Company
3rd Nov 20233:11 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNS2023 Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.